An operating lease is treated like a rental contract. Neither the leased asset nor the associated liability is reported on the lessee balance sheet, but the rights may be very similar to the rights of an owner. The lessee only records the lease payments as a rental expense in income statement.

Adjustments to Financial Statements for Operating Leases
Adjusted Financial Ratios for Operating Leases (Summary)
Adjusted Total Asset Turnover
Adjusted Debt to Equity
Adjusted Return on Assets (ROA)

Bristol-Myers Squibb Co., adjustments to financial statements

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported)	92,603)	95,159)	96,820)	109,314)	118,481)
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Total assets (adjusted)	92,603)	95,159)	96,820)	109,314)	118,481)
Adjustment to Total Debt
Total debt (as reported)	49,649)	39,772)	39,320)	44,553)	50,676)
Add: Operating lease liability (before adoption of FASB Topic 842)²	—)	—)	—)	—)	—)
Add: Current operating lease liabilities	181)	162)	136)	169)	164)
Add: Non-current operating lease liabilities	1,370)	1,530)	1,261)	874)	833)
Total debt (adjusted)	51,200)	41,464)	40,717)	45,596)	51,673)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

^{1, 2} Equal to total present value of future operating lease payments.

Bristol-Myers Squibb Co., Financial Data: Reported vs. Adjusted

Download chart

Bristol-Myers Squibb Co., adjusted financial ratios

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Asset Turnover¹
Reported total asset turnover	0.52	0.47	0.48	0.42	0.36
Adjusted total asset turnover	0.52	0.47	0.48	0.42	0.36
Debt to Equity²
Reported debt to equity	3.04	1.35	1.27	1.24	1.34
Adjusted debt to equity	3.13	1.41	1.31	1.27	1.37
Return on Assets³ (ROA)
Reported ROA	-9.66%	8.43%	6.53%	6.40%	-7.61%
Adjusted ROA	-9.66%	8.43%	6.53%	6.40%	-7.61%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ See details »

² See details »

³ See details »

Financial ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Bristol-Myers Squibb Co. adjusted total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.
Adjusted debt to equity	A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity.	Bristol-Myers Squibb Co. adjusted debt to equity ratio deteriorated from 2022 to 2023 and from 2023 to 2024.
Adjusted ROA	A profitability ratio calculated as net income divided by adjusted total assets.	Bristol-Myers Squibb Co. adjusted ROA improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

Bristol-Myers Squibb Co., Financial Ratios: Reported vs. Adjusted

Download chart

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Revenues	48,300)	45,006)	46,159)	46,385)	42,518)
Total assets	92,603)	95,159)	96,820)	109,314)	118,481)
Activity Ratio
Total asset turnover¹	0.52	0.47	0.48	0.42	0.36
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Revenues	48,300)	45,006)	46,159)	46,385)	42,518)
Adjusted total assets	92,603)	95,159)	96,820)	109,314)	118,481)
Activity Ratio
Adjusted total asset turnover²	0.52	0.47	0.48	0.42	0.36

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ Total asset turnover = Revenues ÷ Total assets
= 48,300 ÷ 92,603 = 0.52

² Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= 48,300 ÷ 92,603 = 0.52

Download chart

Activity ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Bristol-Myers Squibb Co. adjusted total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total debt	49,649)	39,772)	39,320)	44,553)	50,676)
Total BMS shareholders’ equity	16,335)	29,430)	31,061)	35,946)	37,822)
Solvency Ratio
Debt to equity¹	3.04	1.35	1.27	1.24	1.34
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Adjusted total debt	51,200)	41,464)	40,717)	45,596)	51,673)
Total BMS shareholders’ equity	16,335)	29,430)	31,061)	35,946)	37,822)
Solvency Ratio
Adjusted debt to equity²	3.13	1.41	1.31	1.27	1.37

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ Debt to equity = Total debt ÷ Total BMS shareholders’ equity
= 49,649 ÷ 16,335 = 3.04

² Adjusted debt to equity = Adjusted total debt ÷ Total BMS shareholders’ equity
= 51,200 ÷ 16,335 = 3.13

Download chart

Solvency ratio	Description	The company
Adjusted debt-to-equity	A solvency ratio calculated as adjusted total debt divided by total shareholders’ equity.	Bristol-Myers Squibb Co. adjusted debt-to-equity ratio deteriorated from 2022 to 2023 and from 2023 to 2024.

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS	(8,948)	8,025)	6,327)	6,994)	(9,015)
Total assets	92,603)	95,159)	96,820)	109,314)	118,481)
Profitability Ratio
ROA¹	-9.66%	8.43%	6.53%	6.40%	-7.61%
Adjusted for Operating Leases
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS	(8,948)	8,025)	6,327)	6,994)	(9,015)
Adjusted total assets	92,603)	95,159)	96,820)	109,314)	118,481)
Profitability Ratio
Adjusted ROA²	-9.66%	8.43%	6.53%	6.40%	-7.61%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

¹ ROA = 100 × Net earnings (loss) attributable to BMS ÷ Total assets
= 100 × -8,948 ÷ 92,603 = -9.66%

² Adjusted ROA = 100 × Net earnings (loss) attributable to BMS ÷ Adjusted total assets
= 100 × -8,948 ÷ 92,603 = -9.66%

Download chart

Profitability ratio	Description	The company
Adjusted ROA	A profitability ratio calculated as net income divided by adjusted total assets.	Bristol-Myers Squibb Co. adjusted ROA improved from 2022 to 2023 but then deteriorated significantly from 2023 to 2024.

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Operating Leases

Adjustments to Financial Statements for Operating Leases

Bristol-Myers Squibb Co., Financial Data: Reported vs. Adjusted

Adjusted Financial Ratios for Operating Leases (Summary)

Bristol-Myers Squibb Co., Financial Ratios: Reported vs. Adjusted

Adjusted Total Asset Turnover

Adjusted Debt to Equity

Adjusted Return on Assets (ROA)